You are here

  • Home
  • Archive
  • Volume 74, Issue 6
  • MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Østergaard M, Jacobsson LTH, Schaufelberger C, et al
MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16
Annals of the Rheumatic Diseases 2015;74:1156-1163.